Mollie L. Wilson

Mollie L. Wilson

Auto-generated profile, based on publicly available information

Mollie L. Wilson

MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, United Kingdom

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
NYNicholas T. Younger
Nicholas T. Younger
MWMollie L. Wilson
Mollie L. Wilson
ALAnabel Martinez Lyons
Anabel Martinez Lyons
EJEdward J. Jarman
Edward J. Jarman
AMAlison M. Meynert
Alison M. Meynert
LBLuke Boulter
Luke Boulter
Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy of the bile ducts within the liver characterized by high levels of genetic heterogeneity. In the context of such genetic variability, determining which oncogenic mutations drive ICC growth has been difficult, and developing modes of patient stratification and targeted therapies remains challenging. Here we model the interactions between rare mutations with more common driver genes and combine in silico analysis of patient data with highly multiplexed in vivo CRISPR-spCas9 screens to perform a functional in vivo study into the role genetic heterogeneity plays in driving ICC. Novel tumor suppressors were uncovered, which, when lost, cooperate with the RAS oncoprotein to drive ICC growth. Focusing on a set of driver mutations that interact with KRAS to initiate aggressive, sarcomatoid-type ICC revealed that tumor growth relies on Wnt and PI3K signaling. Pharmacologic coinhibition of Wnt and PI3K in vivo impeded ICC growth regardless of mutational profile. Therefore, Wnt and PI3K activity should be considered as a signature by which patients can be stratified for treatment independent of tumor genotype, and inhibitors of these pathways should be levied to treat ICC. Significance: This work shows that, despite significant genetic heterogeneity, intrahepatic cholangiocarcinoma relies on a limited number of signaling pathways to grow, suggesting common therapeutic vulnerabilities across patients.

31 March 2023
Verified
Other
Open access
NYNicholas T. Younger
Nicholas T. Younger
MWMollie L. Wilson
Mollie L. Wilson
ALAnabel Martinez Lyons
Anabel Martinez Lyons
EJEdward J. Jarman
Edward J. Jarman
AMAlison M. Meynert
Alison M. Meynert
LBLuke Boulter
Luke Boulter
Supplementary Data from In Vivo Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma

31 March 2023
Verified
Other
Open access
NYNicholas T. Younger
Nicholas T. Younger
MWMollie L. Wilson
Mollie L. Wilson
ALAnabel Martinez Lyons
Anabel Martinez Lyons
EJEdward J. Jarman
Edward J. Jarman
AMAlison M. Meynert
Alison M. Meynert
LBLuke Boulter
Luke Boulter
Supplementary Data from In Vivo Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma

31 March 2023
Verified
Other
Open access
NYNicholas T. Younger
Nicholas T. Younger
MWMollie L. Wilson
Mollie L. Wilson
ALAnabel Martinez Lyons
Anabel Martinez Lyons
EJEdward J. Jarman
Edward J. Jarman
AMAlison M. Meynert
Alison M. Meynert
LBLuke Boulter
Luke Boulter
Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy of the bile ducts within the liver characterized by high levels of genetic heterogeneity. In the context of such genetic variability, determining which oncogenic mutations drive ICC growth has been difficult, and developing modes of patient stratification and targeted therapies remains challenging. Here we model the interactions between rare mutations with more common driver genes and combine in silico analysis of patient data with highly multiplexed in vivo CRISPR-spCas9 screens to perform a functional in vivo study into the role genetic heterogeneity plays in driving ICC. Novel tumor suppressors were uncovered, which, when lost, cooperate with the RAS oncoprotein to drive ICC growth. Focusing on a set of driver mutations that interact with KRAS to initiate aggressive, sarcomatoid-type ICC revealed that tumor growth relies on Wnt and PI3K signaling. Pharmacologic coinhibition of Wnt and PI3K in vivo impeded ICC growth regardless of mutational profile. Therefore, Wnt and PI3K activity should be considered as a signature by which patients can be stratified for treatment independent of tumor genotype, and inhibitors of these pathways should be levied to treat ICC.Significance:This work shows that, despite significant genetic heterogeneity, intrahepatic cholangiocarcinoma relies on a limited number of signaling pathways to grow, suggesting common therapeutic vulnerabilities across patients.

24 November 2025
Verified
Other
Open access
NYNicholas T. Younger
Nicholas T. Younger
MWMollie L. Wilson
Mollie L. Wilson
ALAnabel Martinez Lyons
Anabel Martinez Lyons
EJEdward J. Jarman
Edward J. Jarman
AMAlison M. Meynert
Alison M. Meynert
LBLuke Boulter
Luke Boulter
Therapeutic coinhibition of Wnt and PI3K signaling reduces tumor growth in ICC. A, RNA-seq data of human ICC demonstrating a positive correlation between the activity of canonical Wnt signaling and Akt signaling. B, Schematic representation of the KPPTom cholangiocarcinoma model where CreERT expression in Keratin-19–positive cholangiocytes results in the inactivation of Trp53 and Pten, whereas labeling transformed cells with tdTomato. C, Representative IHC staining of KPPTom model following tamoxifen administration (day 0) and following 4 and 8 weeks of thioacetamide administration. tdTomato (red) denotes recombined cholangiocytes (denoted by Keratin-19; green). Blue, DNA. Top, whole mount FUNGI images; bottom, 2D histologic sections. Scale bar, 200 μm. White arrows, tdTomato-positive cells. D, Quantification of liver tissue occupied by tumor in the KPPTom ICC model. E, IHC showing that KPPTom ICC has activated canonical Wnt signaling [by staining for dephosphorylated (active) β-catenin] and PI3K activity (through pAKTSer647 positivity). Red arrows, positive cells. Scale bar, 100 μm. F, A schematic representation of how the KPPTom model was used to test the effectiveness of Wnt and Pi3K inhibitor combinations on ICC progression. G, IHC staining for tdTomato-positive cancer cells in vehicle-treated animals compared with those treated with a combination of LGK974 and pictilisib. Scale bar, 100 μm. H, Number of tdTomato-positive cells in KPPTom animals given vehicle or LGK974 and pictilisib in combination. I, Proportion of KPPTom animals containing macroscopic tumors in KPPTom animals treated with vehicle versus combination treatment. b.d., bile duct; p.v., portal vein.

31 March 2023
Verified
Other
Open access
NYNicholas T. Younger
Nicholas T. Younger
MWMollie L. Wilson
Mollie L. Wilson
ALAnabel Martinez Lyons
Anabel Martinez Lyons
EJEdward J. Jarman
Edward J. Jarman
AMAlison M. Meynert
Alison M. Meynert
LBLuke Boulter
Luke Boulter
Supplementary Data from In Vivo Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma